Skip to main
  1. Stocks
  2. Allarity Therapeutics
  3. Forecast
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics is supported by its differentiated DRP platform, which aims to match stenoparib with patients most likely to benefit, improving the probability of success in precision oncology. Its lead asset is showing encouraging Phase 2 evidence in advanced ovarian cancer, with multiple patients exceeding 30 weeks on therapy, two still benefiting beyond 29 months as of March 2026, and median overall survival now exceeding 25 months, while a recurrent SCLC Phase 2 trial began enrolling in February 2026. Financially, the company had $20 million in cash and $22 million in debt in Q1, and the expanding PARP inhibitor market, which generated about $9.0 billion in 2023 and is forecasted to exceed $21.0 billion by 2031, strengthens the long-term opportunity despite development risk.

Bears say

Allarity Therapeutics is exposed to significant balance sheet and liquidity risk, and that financial fragility makes continued funding of its clinical-stage pipeline uncertain. Its outlook is further weakened by the possibility that product candidates may fail to demonstrate safety and efficacy in clinical trials or after FDA or postmarket approval, which would undermine the value of stenoparib and its DRP companion diagnostic. Even if development succeeds, the company still faces regulatory, commercialization, reimbursement, and competitive risks, alongside adverse shifts in patient and physician interest, macroeconomic conditions, biotech investor sentiment, and healthcare priorities.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction

Get the latest Allarity Therapeutics (ALLR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Allarity Therapeutics (ALLR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction

Get the latest Allarity Therapeutics (ALLR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Allarity Therapeutics (ALLR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ALLR stock data and trends